ALPMY News and Press, Astellas Pharma Inc. ADR From 08/20/21

Last month, the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied AstraZeneca (NASDAQ: AZN) and FibroGen 's (NASDAQ: FGEN) drug roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD)....

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor availa...

Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research Astellas' "Future Innovator Prize" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas ...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Astellas Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation

Last week’s 19 IPO week had a lot of life sciences and software. This week, US IPO activity continues at a record with 25 scheduled IPOs, marking the fifth week in 2021 with at least 17 US IPOs, the most since 2000. With the August lull just around the corner, five SPACs raised $895....

U.S. Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients - PROGRAF Becomes First Immunosuppressive Drug Approved in the U.S. for People Receiving a Lung Transplant - PR Newswire...

U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer - Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial - - First and Only FDA-Ap...

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease PR Newswire TOKYO , June 25, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yas...

New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at EHA 2021 Virtual Congress Eight abstracts cover FLT3 mutation-positive AML, patient treatment preferences and utilization in hard-to-treat blood cancer PR Newswire TOKYO , June 8, 2021 /P...

AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...